Skip to main content
Premium Trial:

Request an Annual Quote

Arbitration Panel Rules Operon Must Pay Qiagen $2.1M

NEW YORK (GenomeWeb News) – Operon Biotechnologies must pay Qiagen $2.1 million as a result of an arbitration panel ruling, Qiagen disclosed in a regulatory filing.

In its quarterly earning document filed with the US Securities and Exchange Commission earlier this month, Qiagen said that the arbitration panel ruled in its favor in a supply agreement dispute between the two companies.

In 2009, Operon began arbitration proceedings against Qiagen, claiming Qiagen failed to comply with the preferred supplier provisions of their agreement, resulting in lost profits and other damages. Qiagen disputed the allegations and asserted counterclaims, and in June the arbitration panel ruled in favor of Qiagen on all claims, Qiagen said.

Operon is now Eurofins MWG Operon, based in Ebersberg, Germany, and offers custom oligos, and oligos and sequencing services.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more